Analysts Are Updating Their Zevia PBC (NYSE:ZVIA) Estimates After Its Third-Quarter Results

Zevia PBC (NYSE:ZVIA) just released its quarterly report and things are looking bullish. Revenues and losses per share were both better than expected, with revenues of US$41m leading estimates by 3.3%. Statutory losses were smaller than the analystsexpected, coming in at US$0.04 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the current consensus from Zevia PBC's five analysts is for revenues of US$174.2m in 2026. This would reflect a reasonable 7.0% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 79% to US$0.045. Before this latest report, the consensus had been expecting revenues of US$172.8m and US$0.09 per share in losses. Although the revenue estimates have not really changed Zevia PBC'sfuture looks a little different to the past, with a very favorable reduction to the loss per share forecasts in particular.

See our latest analysis for Zevia PBC

There's been no major changes to the consensus price target of US$4.90, suggesting that reduced loss estimates are not enough to have a long-term positive impact on the stock's valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Zevia PBC at US$6.00 per share, while the most bearish prices it at US$2.90. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Zevia PBC'shistorical trends, as the 5.6% annualised revenue growth to the end of 2026 is roughly in line with the 5.5% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 4.1% annually. So it's pretty clear that Zevia PBC is forecast to grow substantially faster than its industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at US$4.90, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Zevia PBC going out to 2027, and you can see them free on our platform here.

Plus, you should also learn about the 1 warning sign we've spotted with Zevia PBC .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.